Phase 2 N=13 Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation
Graft-versus-host Disease · Hematopoietic Stem Cell Transplantation
Primary: Safety of Maraviroc — 8; 6; 18 Number of AEs
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=40 Comparison of PSAPs in Different Maskers
Auditory Perception
Primary: Comparison of How Four Models of Personal Listening Devices Improve Word Understanding in Noise — 1.65; 0.85; 7.35; 10.24 Percent of words recalled
N/A N=40 Pilot of Pragmatic SBIRT Study
Substance Use Disorders · Pain
Primary: Non-Pharm Pain Treatment Modalities Received — .93; 1.3 non-pharm pain treatments
Phase 2 N=41 Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)
Chikungunya Virus Infection
Primary: Number of Participants With Solicited Adverse Events (AEs) — 15; 11 Participants
Phase 4 N=20 The Effect of Intranasal Oxytocin on Pain Sensitivity and Threshold
Healthy
Primary: Hot and Cold Thermal Sensory Threshold for Pain at Baseline in Degrees Celsius. — 43.93; 43.0; 14.81; 13.33 degrees Celsius — p=.47
N/A N=141 A Comparison of Levalbuterol Plus Ipratropium With Levalbuterol Alone in the Treatment of Acute Asthma Exacerbation
Asthma
Primary: Number of Participants With Bronchodilation — 74; 67 Participants
Phase 2 N=291 Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma
Neuroblastoma
Primary: Efficacy at Completion of Treatment
Phase 2 N=61 Efavirenz in Treating Patients With Metastatic Prostate Cancer
Prostate Cancer
Primary: Percentage of Participants Without Prostate-specific Antigen Progression at 3 Months — 28.3 percentage of participants
N/A N=40 Evaluation of Speech-in-noise Performance in Cochlear Implant Recipients With a CROS Device on the Contralateral Ear
Hearing Loss, Sensorineural
Primary: Cochlear Implant: Signal to Noise Ratio (SNR) Threshold Obtained From IEEE (Speech Perception in Noise Test) Sentence in Noise Test. — 8.45; 10.4; 21.2; 22.2 ratio
Phase 2 N=34 Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability
Alzheimer's Disease
Primary: Changes in Executive Function as Measured by the NIH EXAMINER Computer Battery — -0.06; -0.14 score on a scale — p=0.55
Phase 4 N=54 Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures
Partial Onset Seizures · Secondarily Generalized Seizures · Primary Generalized Tonic-Clonic Seizures
Primary: Percentage of Participants Remaining on Perampanel Treatment at 3 Months After the Initiation of Treatment — 85.2 percentage of participants
Phase 2 N=17 Ides in Highly Sensitized (HS) Patients Awaiting Kidney Transplantation
Renal Disease
Primary: Number of Participants With Allograft Rejection — 7 Participants
Phase 3 N=103 Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Overall Survival of Standard Radiation (CFRT) Versus Accelerated, Hypofractionated, Image-guided Conformal Radiotherapy (IGRT) in Treatment of Stage II-III NSCLC in…
Phase 2 N=31 Evaluation of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD)
Meibomian Gland Dysfunction
Primary: Meibum Gland Secretion Score (MGS) — 0.5; 7.4 score on a scale
Phase 4 N=152 Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout
Gout
Primary: Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6 — 71.0; 38.5 percentage of participants — p=< 0.0001